Mr. Limber has over 35 years of life science experience.  He was previously the CEO and board member of Secura Bio, an oncology pharmaceutical company. Prior to that, Mr. Limber led the acquisition of Genoptix, Inc. from Novartis and served as its CEO and Board member until the sale of Genoptix to NeoGenomics. Mr. Limber previously served as Executive Chairman of ImaginAb and as CEO of Gradalis. Mr. Limber served as CEO and Board member of Prometheus Laboratories and led its acquisition by Nestle Health Science. During his leadership, Prometheus delivered nearly a 30% CAGR in revenue. Mr. Limber was a Board member and interim CEO for Deltagen, Inc., a provider of drug discovery tools and services. Mr. Limber was the CEO and Board member of ACLARA BioSciences, Inc. (now Monogram Biosciences, Inc.), an innovator of lab-on-a-chip technology and he grew the equity value of ACLARA from $48M to over $2 billion.  He was the President & COO of Praecis Pharmaceuticals, Inc. which was acquired by GSK. Prior to Praecis, Mr. Limber served as EVP and interim CEO of SEQUUS Pharmaceuticals which was acquired by Alza and is now part of J&J. He also held senior commercial positions at Syntex Corporation (now F. Hoffmann-La Roche Ltd.) and with Ciba-Geigy Corporation (now Novartis AG). Mr. Limber holds a B.A. from Duquesne University. Mr. Limber is currently a Board member at Xoma Royalty.

Mr. Lund has over 25 years of life science experience.  He was previously the COO & Chief Legal Officer of Secura Bio.  Prior to Secura Bio, he was the Chief Legal Officer of Genoptix where he helped lead the sale of the company to NeoGenomics.  Mr. Lund was also the Chief Legal Officer at Gevo where he led its IPO.  Mr. Lund was the CEO of Agarigen where he led the sale of the company to Intrexon (now Precigen).  He also held senior positions in Syngenta Biotechnology’s biopharma business and was a corporate attorney at the law firm of Cooley LLP. Mr. Lund was named the “Best Corporate Counsel” by Denver Business Journal, “Forty Under 40” by Denver Business Journal and one of the “Most Influential Young Professionals” by ColoradoBiz Magazine.  Mr. Lund is currently on the Board of TRAX International and previously served on the Boards of Agarigen, Colorado BioScience Association, Colorado Cleantech Industry Association and Gevo Development.  Mr. Lund holds a JD from Duke Law School and an MBA from Duke University’s Fuqua School of Business.

Mr. Davis has over 25 years of experience in global marketing, brand development, strategic pricing and contracting, national sales strategy and sales training implementation for oncology brand launches in the biotechnology industry. He most recently served as EVP, Commercial Operations for HUYABIO where he led commercial activities for all of their therapeutics.  Prior to HUYABIO, Mr. Davis was the SVP, Commercial Operations for Secura Bio, where he led global sales, marketing, market access, pricing, and contracting during the commercial launch of duvelisib and panobinostat, and subsequently developed the sales, marketing, clinical affairs and business development departments. He was the SVP, Oncology Sales and Marketing at Fulgent Genetics, where he designed and launched the strategic marketing plan, multiple marketing campaigns, pricing strategies, and all marketing material for clinical diagnostic genetic sequencing biotechnology products. He previously held senior positions at Genoptics, Amgen, J&J, and Pharmacia. Mr. Davis received his BA in Business Administration from California State University San Bernadino. 

Dr. Sulley has over 35 years of experience in biotech and the pharmaceutical industry. Prior to Garda, Dr. Sulley was the SVP, Global Regulatory Affairs and Technology Operations at Secura Bio, Inc. Prior to joining Secura Bio, she was President and Member of the Board of Directors of Tamir Biotechnology (acquired by Orgenesis), Chief Operating Officer of Tensys Medical (acquired by Shanshi), General Manager for Pharmalink Consulting (acquired by Genpact), and former President of TCSI and JASA. She has grown and expanded pharmaceutical and med tech companies providing global leadership and support for FDA, EMA, MHRA and other health agency regulatory activities at the C-suite level. Dr. Sulley has brought drug development programs from proof of concept through to global commercialization for New Chemical Entity (NCE), 505(b)(1) and 505(b)(2) products that have encompassed small molecules, biologics, and combination products leveraging her experience as an accredited FDA reviewer. She holds BS and PHD in Chemistry and a MPH from University of Liverpool.

Mr. Pillai has nearly 20 years of experience in corporate finance, financial planning & analysis, and business development across the life science and technology sectors. He is currently a finance and investment consultant focused on identifying regional biopharma investments and providing strategic planning and modeling from funding through divestment. Mr. Pillai has held progressive FP&A and business development leadership roles at multiple biotech and pharmaceutical companies, where he worked directly with C-level executives on M&A opportunities, multi-year strategic planning, and growth strategies. He has extensive experience in complex financial and business modeling, budgeting, forecasting, M&A valuations, and due diligence. Mr. Pillai has also led cross-functional teams in evaluating early-stage pipeline assets and engaging potential partners across large and mid-size life science firms. He holds a B.A. in Economics from UC San Diego and an MBA from San Diego State University.